• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

国际临床化学与检验医学联合会心脏损伤标志物标准化委员会:前提与项目介绍

IFCC Committee on Standardization of Markers of Cardiac Damage: Premises and Project Presentation.

出版信息

EJIFCC. 1999 Jul 7;11(2):45-48. eCollection 1999 Jul.

PMID:30720255
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6357248/
Abstract

The field of biochemical markers of cardiac damage is in a dynamic state, with new applications continually appearing and new assays and markers being developed. These significant and rapid advancements in the development of new biochemical assays have led, however, to several analytic and interpretative problems. In this situation, it is essential that a uniform and rigorous outlook be maintained to ensure optimal test utilization. For these reasons, the IFCC Scientific Division recently agreed to establish a Committee on "Standardization of Markers of Cardiac Damage" (C-SMCD), inviting members from the already established American and European groups to become members of this Committee. In this presentation, the premises, the issues, and the proposed plan of action of C-SMCD are presented and discussed.

摘要

心脏损伤生化标志物领域处于动态发展中,新的应用不断涌现,新的检测方法和标志物也在不断研发。然而,新生化检测方法的这些重大且迅速的进展带来了一些分析和解释方面的问题。在这种情况下,保持统一且严谨的观点以确保最佳检测应用至关重要。基于这些原因,国际临床化学与检验医学联合会(IFCC)科学部最近同意成立一个“心脏损伤标志物标准化委员会”(C-SMCD),邀请已成立的美国和欧洲团体的成员加入该委员会。在本报告中,将介绍并讨论C-SMCD的前提、问题及拟议的行动计划。

相似文献

1
IFCC Committee on Standardization of Markers of Cardiac Damage: Premises and Project Presentation.国际临床化学与检验医学联合会心脏损伤标志物标准化委员会:前提与项目介绍
EJIFCC. 1999 Jul 7;11(2):45-48. eCollection 1999 Jul.
2
IFCC Committee on Standardization of Markers of Cardiac Damage: premises and project presentation. International Federation of Clinical Chemistry and Laboratory Medicine.国际临床化学和检验医学联合会心脏损伤标志物标准化委员会:工作前提与项目介绍
Clin Chem Lab Med. 1998 Nov;36(11):887-93. doi: 10.1515/CCLM.1998.155.
3
Standardization activities of markers of cardiac damage: the need of a comprehensive approach.心脏损伤标志物的标准化活动:综合方法的必要性。
Eur Heart J. 1998 Nov;19 Suppl N:N8-11.
4
Proposals from the IFCC Committee on Standardization of Markers of Cardiac Damage (C-SMCD): strategies and concepts on standardization of cardiac marker assays.国际临床化学与检验医学联合会心脏损伤标志物标准化委员会(C-SMCD)的提议:心脏标志物检测标准化的策略与概念
Scand J Clin Lab Invest Suppl. 1999;230:113-23.
5
Use of biochemical markers in acute coronary syndromes. IFCC Scientific Division, Committee on Standardization of Markers of Cardiac Damage. International Federation of Clinical Chemistry.生化标志物在急性冠脉综合征中的应用。国际临床化学联合会科学部,心脏损伤标志物标准化委员会。
Clin Chem Lab Med. 1999 Jun;37(6):687-93. doi: 10.1515/CCLM.1999.107.
6
Proposals from IFCC Committee on Standardization of Markers of Cardiac Damage (C-SMCD): recommendations on use of biochemical markers of cardiac damage in acute coronary syndromes.国际临床化学和检验医学联合会心脏损伤标志物标准化委员会(C-SMCD)的提议:关于急性冠状动脉综合征中心脏损伤生化标志物使用的建议。
Scand J Clin Lab Invest Suppl. 1999;230:103-12.
7
An overview and ranking of biochemical markers of cardiac disease. Strengths and limitations.心脏病生化标志物概述与排名。优势与局限性。
Clin Lab Med. 1997 Dec;17(4):625-54.
8
Standardization of cardiac markers.心脏标志物的标准化
Scand J Clin Lab Invest Suppl. 2005;240:107-11. doi: 10.1080/00365510500236242.
9
Analytical and assay issues for use of cardiac troponin testing for risk stratification in primary care.用于初级保健中心风险分层的心肌肌钙蛋白检测的分析和检测问题。
Clin Biochem. 2013 Aug;46(12):969-978. doi: 10.1016/j.clinbiochem.2013.04.013. Epub 2013 Apr 25.
10
IFCC committee on markers for bone turnover and bone disease--project presentation.国际临床化学与检验医学联合会骨转换与骨疾病标志物委员会——项目介绍
Scand J Clin Lab Invest Suppl. 1997;227:95-9.

本文引用的文献

1
Multicenter evaluation of five assays for myoglobin determination.五种肌红蛋白测定方法的多中心评估。
Clin Chem. 2000 Oct;46(10):1631-7.
2
Diagnostic application of CK-MB mass determination.肌酸激酶同工酶质量测定的诊断应用。
Clin Chim Acta. 1998 Apr 6;272(1):23-31. doi: 10.1016/s0009-8981(97)00249-0.
3
Proficiency testing of creatine kinase and creatine kinase-2: the experience of the Ontario Laboratory Proficiency Testing Program.
Clin Chem. 1998 Jan;44(1):124-33.
4
Spectrum of ischemic heart disease and the role of biochemical markers.缺血性心脏病的谱系及生化标志物的作用
Clin Lab Med. 1997 Dec;17(4):701-25.
5
Applicability of cardiac troponin T and I for early risk stratification in unstable coronary artery disease. TRIM Study Group. Thrombin Inhibition in Myocardial ischemia.心肌肌钙蛋白T和I在不稳定型冠状动脉疾病早期风险分层中的适用性。TRIM研究组。心肌缺血中的凝血酶抑制。
Circulation. 1997 Oct 21;96(8):2578-85. doi: 10.1161/01.cir.96.8.2578.
6
Rapid, highly sensitive immunoassay for determination of cardiac troponin I in patients with myocardial cell damage.用于测定心肌细胞损伤患者心肌肌钙蛋白I的快速、高灵敏度免疫测定法。
Clin Chem. 1997 Aug;43(8 Pt 1):1464-5.
7
Automated immunoassay of cardiac Troponin I in serum evaluated.血清中心肌肌钙蛋白I的自动化免疫分析评估。
Clin Chem. 1997 Jan;43(1):195-6.
8
Troponin T: a diagnostic marker for myocardial infarction and minor cardiac cell damage.
Eur Heart J. 1996 Dec;17 Suppl F:3-8. doi: 10.1093/eurheartj/17.suppl_f.3.
9
ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction).美国心脏病学会/美国心脏协会急性心肌梗死患者管理指南。美国心脏病学会/美国心脏协会实践指南工作组(急性心肌梗死管理委员会)报告。
J Am Coll Cardiol. 1996 Nov 1;28(5):1328-428. doi: 10.1016/s0735-1097(96)00392-0.
10
Enzyme and muscle diseases.
Curr Opin Rheumatol. 1995 Nov;7(6):469-74. doi: 10.1097/00002281-199511000-00003.